Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Diagnosed with NASH? Consider our FALCON 1 clinical research study

Information for potential participants

It may be hard to understand today, but your liver might thank you tomorrow.

It may be hard to understand today, but your liver might thank you tomorrow.

Being told that you are living with non-alcoholic steatohepatitis (NASH) can come as a bit of a shock, especially if you’ve experienced few or no symptoms of the disease. Because NASH is often symptomless, many people don’t know they have it until it leads to further problems.

What does this clinical research study involve?

The total length of the study is up to approximately 28 months.

*A placebo is an inactive drug that has no treatment value. In the FALCON 1 study, 1 out of every 4 participants will be assigned the placebo. As this study is ‘double-blind’ you won’t know which group you are assigned to and neither will the study team. This helps us to be sure that any changes seen are due to the study drug alone and not some other factor (such as increased monitoring).

You won’t be asked for any personal information until after you have completed the questionnaire and decided to proceed.

Who is at risk of NASH?

Research suggests that certain health conditions make you more likely to have or develop NASH. These include:

What are the current treatment options?

Currently, there are no approved treatment options for NASH. Many doctors recommend losing weight, as research suggests this helps to reduce the liver fat and scarring associated with the condition. However, many people struggle to make such lifestyle changes. Because of this, there is a significant need for new NASH drugs to be developed.

  • More about NASH

    Non-alcoholic steatohepatitis (NASH) is a disease that affects people who have an inflamed and damaged liver due to the build-up of fats in their liver. Although many people with NASH experience few symptoms, it often results in scarring of the liver known as ‘fibrosis.’ Over time, fibrosis can progress to cirrhosis of the liver.
  • What is Cirrhosis?

    Cirrhosis is the liver damage caused when scar tissue replaces normal tissue and it is the main complication of NASH. It can take many years to develop, often without any noticeable symptoms. There are 2 main stages of cirrhosis – compensated and decompensated. Compensated cirrhosis means that the liver is heavily scarred but can still perform many of its important functions. Too much scarring and the liver will run out of healthy cells to function properly – this is decompensated cirrhosis, which can result in liver failure.
  • What are early symptoms of compensated cirrhosis?

    Fatigue and loss of energy Loss of appetite and weight loss Nausea or abdominal pain Spider angiomas that may develop on the skin. These are pinhead-sized red spots from which tiny blood vessels radiate outward.

Have questions? Call 855-907-3286 or Email Us

Have questions?
Call 855-907-3286 or Email Us